Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer

5 Oct 2023

Abstract excerpt

BACKGROUND: Androgen receptor (AR) pathway inhibition remains the cornerstone for prostate cancer therapies. However, castration-resistant prostate cancer (CRPC) tumors can resist AR signaling inhibitors through AR amplification and AR splice variants in AR-positive CRPC (ARPC), and conversion to AR-null phenotypes, such as double-negative prostate cancer (DNPC) and small cell or neuroendocrine prostate cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibroblast Growth Factor Research
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37796107
DOI: 10.1002/pros.24630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancerPMID 37796107Read ↗

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor SignalingSemantic proximity Read ↗

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.Semantic proximity Read ↗

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responsesSemantic proximity Read ↗

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation TherapySemantic proximity Read ↗

A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.Semantic proximity Read ↗

Development and prevalence of castration-resistant prostate cancer subtypesSemantic proximity Read ↗

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.Semantic proximity Read ↗

Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancerSemantic proximity Read ↗

PHENOTYPIC CHARACTERIZATION OF TWO NOVEL CELL LINE MODELS OF CASTRATION RESISTANT PROSTATE CANCERSemantic proximity Read ↗

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.